Yet, tumors from guadecitabine/ICBs treated animals displayed a significantly lower amount of CD206+ M2 close to CD8+ T cells, but relatively high percentages of CD206- macrophages, suggestive of the establishment of a productive anti-tumor crosstalk. The gene discussed is MRC1; the disease is neoplasm.